Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589363 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL10592428 | 0.94 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL2584027 | 0.93 | SLC28A1 (0.52) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL8390570 | 0.91 | SLC28A1 (0.54) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL1317089 | 0.91 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL918582 | 0.91 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL918583 | 0.91 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL26502752 | 0.91 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL12434636 | 0.91 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL12513082 | 0.91 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629447-B2 | Dideoxynucleoside derivatives | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20080064868-A1 | Novel Dideoxynucleoside Derivatives | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064868-A1 | Novel Dideoxynucleoside Derivatives | DNA2, DDX20, DNASE1 | TYMP 251/4885P2RY14 2886/4885P2RY2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.